Asset Details
Do you wish to reserve the book?
Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
Do you wish to request the book?
Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
2018
Overview
Background
Cardiovascular complications are common in kidney transplant patients and calcification propensity of blood, measured as T
50
, is associated with cardiovascular outcomes. Paricalcitol supplementation affects calcium/phosphate homeostasis and may affect calcification propensity. To assess this hypothesis we measured T
50
in kidney transplant recipients participating in a randomized study comparing paricalcitol versus no treatment during the first year after kidney transplantation.
Methods
Stored serum samples from 76 kidney transplant recipients (paricalcitol
n
= 37, no treatment
n
= 39) were analyzed. Analyses were performed at inclusion (8 weeks after transplantation) and repeated one year after transplantation.
Results
There were no statistically significant differences in T
50
between the paricalcitol and placebo groups, neither at baseline (
p
= 0.56) nor at 1 year (
p
= 0.61). Also, there were no significant changes in T
50
over time in either group or when pooling all data (
p
< 0.20). In multivariate regression analysis, out of 16 potentially relevant covariates, comprising clinical and biochemical parameters, only plasma PTH and T
50
at baseline were significantly correlated to T
50
after one year. (
p
< 0.03 and
p
< 0.01, respectively).
Conclusions
Calcium propensity measured as T
50
score remained unchanged with paricalcitol treatment in kidney transplant recipients, and was not changed over time during the study period of one year.
Trial registration
ClinicalTrials.gov,
NCT01694160
, registered 23 September 2012.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Aged
/ Bone Density Conservation Agents - administration & dosage
/ Bone Density Conservation Agents - adverse effects
/ Calcification propensity score
/ Calcinosis - chemically induced
/ Ergocalciferols - administration & dosage
/ Ergocalciferols - adverse effects
/ Female
/ Humans
/ Kidney Transplantation - adverse effects
/ Kidney Transplantation - trends
/ Kidneys
/ Male
/ Medicine
/ Renal Insufficiency, Chronic - blood
/ Renal Insufficiency, Chronic - epidemiology
/ Renal Insufficiency, Chronic - therapy
/ Studies
